Karyopharm - oncology

Quote

anonymous said:
I think someone "knew something about ten quarters ago" take a look at the chart. No company is riding to save this idiot, knowing he will sink the ship all on his own doing and they can get for free practically. Why save him when it’s so much more fun watching him trip, stumble and fall while he shits the bed. True comedy and couldnt happen to a better guy.
Click to expand...
No doubt…
 





















anonymous said:
In case you’re keeping track. Stock down over 93 percent last two years.
Click to expand...
Many biotechs await readouts and are faced with cash flow challenges. Their CEO’s, the good ones at least, manage the uncertainty that Wall Street has in an effective manner as not to loose all enterprise value prior to the next event.

R has failed miserably, which should not be a surprise based on his lackluster resume. He’s never been accountable to anything close to this while at Amgen or Ipsen. This was not the time nor the company for the ‘grow into the role’ hire.

“We” did this to ourselves.
 



anonymous said:
Criminal
Click to expand...
Remember How to File a Charge of Employment Discrimination and to personally name the individual boss, manager or supervisor that is responsible for the discriminatory or otherwise unlawful employment practice. This is particularly true where the company boss is the perpetrator and attempting to shield himself or herself from liability by closing a corporate shell. The boss is living in a mansion and driving a new expensive automobile from their ill gotten executive compensation while claiming the company is broke. Employment laws allow the wronged employee to sue the boss directly for his or her own wrongful or discriminatory conduct when all lawsuits are stayed in bankruptcy.
 



anonymous said:
Many biotechs await readouts and are faced with cash flow challenges. Their CEO’s, the good ones at least, manage the uncertainty that Wall Street has in an effective manner as not to loose all enterprise value prior to the next event.

R has failed miserably, which should not be a surprise based on his lackluster resume. He’s never been accountable to anything close to this while at Amgen or Ipsen. This was not the time nor the company for the ‘grow into the role’ hire.

“We” did this to ourselves.
Click to expand...
This!!!
 






anonymous said:
Many biotechs await readouts and are faced with cash flow challenges. Their CEO’s, the good ones at least, manage the uncertainty that Wall Street has in an effective manner as not to loose all enterprise value prior to the next event.

R has failed miserably, which should not be a surprise based on his lackluster resume. He’s never been accountable to anything close to this while at Amgen or Ipsen. This was not the time nor the company for the ‘grow into the role’ hire.

“We” did this to ourselves.
Click to expand...
Exactly!!!! R has no experience whatsoever, and we have been watching is failures first hand. S is no better. Minimal experience, yet she barks orders likes she’s ever accomplished anything in this industry.
 





















Top Bottom
Back
Quote